Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-11, Vol.385 (19), p.1774-1785
Hauptverfasser:	El Sahly, Hana M, Baden, Lindsey R, Essink, Brandon, Doblecki-Lewis, Susanne, Martin, Judith M, Anderson, Evan J, Campbell, Thomas B, Clark, Jesse, Jackson, Lisa A, Fichtenbaum, Carl J, Zervos, Marcus, Rankin, Bruce, Eder, Frank, Feldman, Gregory, Kennelly, Christina, Han-Conrad, Laurie, Levin, Michael, Neuzil, Kathleen M, Corey, Lawrence, Gilbert, Peter, Janes, Holly, Follmann, Dean, Marovich, Mary, Polakowski, Laura, Mascola, John R, Ledgerwood, Julie E, Graham, Barney S, August, Allison, Clouting, Heather, Deng, Weiping, Han, Shu, Leav, Brett, Manzo, Deb, Pajon, Rolando, Schödel, Florian, Tomassini, Joanne E, Zhou, Honghong, Miller, Jacqueline
Format:	Artikel
Sprache:	eng
Schlagworte:	2019-nCoV Vaccine mRNA-1273 Adolescent Adult Aged Allergies Asymptomatic Asymptomatic infection Clinical trials Consent Coronavirus Coronaviruses COVID-19 COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - adverse effects COVID-19 Vaccines - immunology Follow-Up Studies Humans Immunization Immunization, Secondary Immunogenicity, Vaccine Incidence Infections Infectious Disease Infectious diseases Injection Injections Intention to Treat Analysis Male Middle Aged mRNA Original Patient Acuity Placebos Population Safety Severe acute respiratory syndrome coronavirus 2 Single-Blind Method Statistical analysis Treatment Outcome Vaccine efficacy Vaccines Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The mRNA-1273 vaccine was approved for emergency use in December 2020; trial participants who received placebo were informed of the results and offered vaccination. At the close of the blinded phase of the trial, the vaccine efficacy in preventing Covid-19 illness was 93.2%, and the efficacy against severe disease was 98.2%. No new safety issues were identified.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa2113017